Hormone Therapy Risk FAQs: Breast Cancer, Clots | ACT 2

Question 1

How much does hormone therapy raise breast cancer risk in absolute terms?

Accepted Answer

Stated as cases rather than percentages, the increase seen in the Women's Health Initiative's estrogen-plus-progestin arm amounted to well under one additional breast cancer per thousand women per year. That is a real number and a small one, of the same order as several everyday exposures people already weigh without panic, and the relative-risk reporting that made headlines in 2002 made it impossible to judge. The estrogen-alone arm did not show that signal at all. Your own baseline risk, which progestogen is used and how long you take it all move the figure, so it is weighed against what your symptoms are costing rather than read off a page.

Question 2

Does estradiol on its own cause breast cancer?

Accepted Answer

Estrogen given on its own has not been shown to increase breast cancer, and long-term follow-up of the Women's Health Initiative's estrogen-alone arm has been reported as showing fewer breast cancers than placebo rather than more. The increase that drove two decades of caution came from the arm combining estrogen with a synthetic progestin, and later cohort work points at the progestogen as the variable that mattered. None of that is a clean bill for every woman: a personal history of breast cancer, or a strong family history, changes the assessment and is worked through with a clinician.

Question 3

Which progestogen did the Women's Health Initiative actually use?

Accepted Answer

The Women's Health Initiative's combined arm used medroxyprogesterone acetate, a synthetic progestin, alongside conjugated equine estrogen. Every conclusion drawn from that arm is therefore a conclusion about those two molecules, not about estradiol with micronized progesterone, which is what most women are offered now. Reading a finding about one progestin as a finding about progesterone in general is the single largest source of confusion in this subject.

Question 4

Does micronized progesterone carry the same breast cancer risk as a synthetic progestin?

Accepted Answer

Micronized progesterone appears to carry less breast cancer risk than synthetic progestins, on evidence that is observational rather than randomized. The French E3N cohort found no significant increase with estrogen plus micronized progesterone over the first several years of use, against a clear increase with other progestins, and the pattern has been reproduced in other European cohorts. Less is not none — pooled data suggest a small excess with any combined therapy beyond roughly five years, which is a reason to review the decision rather than assume it settled.

Question 5

Does the breast cancer risk of hormone therapy grow the longer you take it?

Accepted Answer

The breast cancer signal in combined hormone therapy is concentrated in longer use. A large 2019 meta-analysis found some excess with every form of combined therapy, including estrogen with micronized progesterone, once use extended beyond about five years — smaller with progesterone than with synthetic progestins, and not zero. That makes five years a sensible point to restate the reasons for continuing with your clinician, rather than a deadline at which anyone has to stop.

Question 6

Does the route of estrogen change breast cancer risk?

Accepted Answer

Route changes clot and stroke risk substantially; it is not clearly established to change breast cancer risk. Choosing a patch or a gel over a pill is therefore a decision about clotting and blood pressure rather than about the breast. Which progestogen accompanies the estrogen matters more to breast risk than which route the estrogen takes.

Question 7

Why did the FDA remove the breast cancer boxed warning from hormone therapy?

Accepted Answer

The FDA removed the boxed warnings for breast cancer, cardiovascular disease and probable dementia from menopausal hormone therapy products because those warnings rested on a trial of women who were, on average, in their sixties and more than a decade past menopause, taking a combination that is no longer typical — and the evidence in women starting near menopause did not support applying one blanket caution to every woman and every formulation. Breast cancer risk did not vanish from the label; it sits in the warnings section, described as the evidence supports. One boxed warning was deliberately kept: endometrial cancer, on estrogen-alone products, for women who still have a uterus.

Question 8

Can I take systemic hormone therapy after breast cancer?

Accepted Answer

Systemic hormone therapy is generally not offered after breast cancer — trials that tested it were stopped when recurrence rose, and that position has not changed. Local vaginal estrogen is a separate question with a different absorption profile and considerably more reassuring data. Non-hormonal treatments exist for hot flashes and for vaginal symptoms, and any hormonal decision here is made with your oncology team rather than around them.

Question 9

Can I use vaginal estrogen if I am taking an aromatase inhibitor?

Accepted Answer

An aromatase inhibitor is the part of this question where caution is genuinely warranted, because those drugs work by driving estrogen as close to zero as possible, so even small absorption acts against a suppressed baseline rather than an ordinary postmenopausal one. Some studies have found measurable rises in blood estradiol in aromatase-inhibitor users on vaginal estrogen; whether that changes outcomes is not established. The usual sequence is non-hormonal moisturizers and lubricants first, used properly and for long enough, with anything beyond that decided with the oncologist's documented agreement. Tamoxifen works differently — it blocks the receptor rather than removing estrogen — and the concern there is correspondingly smaller.

Question 10

Does a BRCA mutation rule out hormone therapy?

Accepted Answer

A BRCA mutation does not automatically rule out hormone therapy, and the situation it most often arises in — a woman whose ovaries were removed young to reduce cancer risk — is one where early estrogen loss carries its own substantial cost to bone, heart and brain. What the decision turns on is whether you have had breast cancer, whether the ovaries and breasts have been removed, and how old you are now. It is made with the team managing your cancer risk, and it is not a question to settle from a page.

Question 11

Do I still need mammograms while taking hormone therapy?

Accepted Answer

Breast screening continues on schedule throughout hormone therapy — that is part of the plan rather than a caveat attached to it. Hormone therapy can increase breast density on a mammogram, which sometimes makes films harder to read and occasionally prompts extra views, so it is worth telling the imaging service what you are taking. Any new lump, skin change or nipple discharge is investigated exactly as it would be if you were on nothing.

Question 12

Does the estradiol patch cause blood clots?

Accepted Answer

Transdermal estradiol has consistently shown little or no increase in venous clot risk compared with no treatment, while oral estrogen roughly doubles it. The difference is mechanical: anything swallowed reaches the liver at high concentration before the rest of the body and shifts the liver's production of clotting factors, and a patch bypasses that entirely. The evidence for the route difference is observational rather than randomized — consistent, and worth knowing for what it is when you hear it stated as certainty.

Question 13

Can I use an estrogen patch if I have had a blood clot?

Accepted Answer

Sometimes, and never automatically. Oral estrogen is generally not offered to a woman who has had a deep vein thrombosis or pulmonary embolism; whether a patch is possible depends on why the clot happened, whether you are anticoagulated, and input from whoever manages your clotting history. An acute or recent clot rules systemic estrogen out for the time being. Where it stays ruled out, vaginal estrogen for local symptoms and non-hormonal options for the rest are the honest answer rather than a consolation prize.

Question 14

I have Factor V Leiden. Can I take estrogen?

Accepted Answer

Factor V Leiden in someone who has never had a clot is one of the clearest arguments for the transdermal route: transdermal estrogen appears not to add meaningfully to a carrier's baseline risk, where oral estrogen multiplies it. The same logic applies to prothrombin gene mutation and to protein C or S deficiency. It remains a conversation that involves your full history and often a hematologist, and a clotting disorder that has already produced events despite anticoagulation is a different situation.

Question 15

Does transdermal estrogen mean there is no clot risk at all?

Accepted Answer

No. The reassuring finding about transdermal estrogen is observational and describes populations rather than you: it says the average excess over no treatment is small or undetectable, not that any individual is protected. Your own risk still depends on your clot history, any inherited clotting disorder, weight, smoking, immobility and recent surgery, which is what the assessment before prescribing is for. New leg swelling, chest pain or breathlessness is urgent whatever route you are using.

Question 16

Does being overweight change which estrogen route is safer?

Accepted Answer

Excess weight is itself a risk factor for venous clots and oral estrogen compounds it, so transdermal delivery is the default route in most guidance for a woman carrying significant extra weight. Weight also shapes the wider conversation, because it moves blood pressure, glucose and several of the symptoms being treated. It does not by itself rule hormone therapy out.

Question 17

Does progesterone affect blood clot risk?

Accepted Answer

Micronized progesterone does not appear to add to clot risk on the available evidence, while synthetic progestins — medroxyprogesterone acetate in particular — appear to. That is why a woman using a patch specifically because of clot risk is generally paired with micronized progesterone rather than a progestin. The estrogen route remains the larger part of the picture; the progestogen is the rest of it.

Question 18

Does hormone therapy increase the risk of stroke?

Accepted Answer

Oral estrogen was associated with an excess of strokes in the Women's Health Initiative, whose participants averaged their early sixties, and that excess appears attenuated or absent with transdermal estrogen at standard strengths — though the stroke evidence is less complete than the evidence on venous clots. Baseline stroke risk below 60 is low, so a small relative increase is a small absolute one at that age and a larger one later. A previous stroke or transient ischemic attack changes the answer and is assessed with the clinician managing it.

Question 19

Does hormone therapy raise blood pressure?

Accepted Answer

Oral estrogen can raise blood pressure in some women, through the same first pass through the liver that governs clot risk — the liver alters its production of angiotensinogen, a precursor in the system regulating blood pressure. Transdermal estradiol is generally regarded as blood-pressure neutral, which is why route is the main lever when blood pressure is a concern. Blood pressure is measured before starting and rechecked on treatment rather than assumed, and a raised reading found at a hormone consultation is a useful finding in its own right.

Question 20

Can I take hormone therapy after a heart attack or a stroke?

Accepted Answer

Established cardiovascular disease — a previous heart attack, stroke or transient ischemic attack — is one of the situations in which systemic hormone therapy is generally not started, and where it is considered at all that happens with the cardiologist or neurologist involved. Hormone therapy is not prescribed to prevent cardiovascular disease, so there is no benefit on that side of the ledger to weigh against the risk. Non-hormonal treatments for hot flashes, and local vaginal estrogen for genitourinary symptoms, are usually the route in that situation.

Question 21

Is hormone therapy safe if I have fibroids or endometriosis?

Accepted Answer

Fibroids and endometriosis are generally manageable on hormone therapy rather than disqualifying, though both influence the choice of regimen because estrogen can stimulate the tissue involved. New or heavier bleeding, or pelvic pain that changes character, is investigated rather than attributed to the prescription. A woman whose hysterectomy was for endometriosis is sometimes kept on a progestogen even though there is no longer an endometrium to protect, because endometrial tissue may remain elsewhere.

Question 22

Does estrogen without progesterone cause endometrial cancer?

Accepted Answer

Systemic estrogen taken without a progestogen by a woman who still has a uterus stimulates the endometrium, and over years that stimulation carries a real and well-established risk of endometrial cancer. It is the one hormone therapy risk the FDA kept as a boxed warning when it removed the others, which is a fair reflection of how solid the evidence is. A progestogen is added to prevent exactly this, which is why it is not optional and not a matter of preference.

Question 23

Can I skip progesterone if it makes me feel terrible?

Accepted Answer

Stopping the progestogen while continuing systemic estrogen is not a safe option for a woman with a uterus, because endometrial protection is the entire reason it is there. Progesterone side effects — drowsiness, low mood, bloating — are common enough to be worth solving rather than enduring, and the usual moves are a change of timing, a change of form or a different progestogen. That is a conversation with the prescriber, not a decision to make alone at home.

Question 24

Is bleeding on hormone therapy something to worry about?

Accepted Answer

Unscheduled bleeding in the first months of hormone therapy is common and usually settles, but bleeding that starts after a settled stretch, continues beyond the first few months, or happens to a woman who was fully postmenopausal before starting is investigated rather than watched. The investigation is looking for endometrial thickening or cancer, and finding nothing is the usual outcome. No amount of hormone therapy makes postmenopausal bleeding normal.

Question 25

Is it safe to swap progesterone capsules for a cream?

Accepted Answer

Substituting a cream for oral micronized progesterone while continuing systemic estrogen leaves the endometrium unprotected, which makes it one of the few genuinely unsafe moves a person can make with these products. Absorption through skin is modest and variable, the amount reaching the lining is too low to counter estrogen's effect on it, and studies that looked found lining changes on estrogen plus cream that an oral progestogen prevents. If oral progesterone is causing problems, the fix is a change made with the prescriber rather than a quiet swap at home. See menopause and hormone therapy for what each form is for.

Question 26

Does vaginal estrogen carry the same risks as systemic hormone therapy?

Accepted Answer

Vaginal estrogen acts where it is placed, and blood estradiol in women using it at standard strengths stays within or close to the untreated postmenopausal range — so the clot, stroke and breast risk discussion that applies to systemic therapy does not transfer to it. It does not routinely require a progestogen for endometrial protection either. The FDA's removal of boxed warnings covered vaginal products too, which had for years carried a systemic-therapy warning that never described their actual absorption. See menopause and hormone therapy for what it treats.

Question 27

Is vaginal estrogen safe to use for years?

Accepted Answer

Vaginal estrogen is intended for ongoing use, because the tissue changes it treats return within months of stopping — it manages a condition rather than curing one. Minimal systemic absorption is what makes indefinite use reasonable, and no routine stop date applies at any age. Any postmenopausal bleeding while using it is still investigated.

Question 28

Is estriol safer than estradiol for vaginal use?

Accepted Answer

Estriol is a weaker estrogen than estradiol and the theoretical case for preferring it locally is reasonable, but the outcome data do not clearly separate the two and both fall within what guidance calls local vaginal estrogen. Estriol is not available as an FDA-approved product in the United States, so any estriol preparation is compounded: compounded medications are not FDA-approved, are not reviewed by the FDA for safety or effectiveness, and are not equivalent to or interchangeable with any branded product. Which suits you is a clinical decision rather than a ranking.

Question 29

Does hormone therapy cause dementia?

Accepted Answer

Probable dementia was one of the three boxed warnings the FDA removed from menopausal hormone therapy products, and the signal behind it came from women who began therapy in their mid-sixties or later rather than near menopause. Hormone therapy is also not prescribed to protect cognition, and no major guideline recommends it for that purpose — anyone selling it on that basis is ahead of the evidence. Brain fog during the transition is a different question from dementia risk and usually has a different explanation.

Question 30

Does hormone therapy cause gallbladder problems?

Accepted Answer

Oral estrogen is associated with an increased risk of gallstones and gallbladder surgery, and that association is much weaker or absent with estrogen absorbed through the skin — another consequence of what the liver sees when a hormone is swallowed. A history of gallbladder disease is therefore a reason to discuss the route rather than a reason to rule hormone therapy out, and it belongs in the assessment rather than being mentioned afterward.

Question 31

Is there an age at which hormone therapy has to be stopped?

Accepted Answer

No. The arbitrary five-year rule and the automatic stop at 60 have been retired by the major menopause societies, and continuing past either is a periodic review rather than a prohibition. What changes with age is the balance: background cardiovascular and breast risk rise, so the reasons for continuing are restated at each review and the route is often part of that conversation. Being over 60 and already on treatment is a different question from starting over 60, and the two get confused constantly.

Question 32

Is it dangerous to stop hormone therapy suddenly?

Accepted Answer

Stopping hormone therapy suddenly is not dangerous, though it is more likely to produce a noticeable rebound in symptoms over the first weeks than reducing gradually. What returns is not withdrawal — it is the symptoms that were being treated becoming apparent again, which is why they can persist rather than pass. Bone protection is not retained after stopping either, so bone loss resumes, and that belongs in the decision rather than being discovered later.

Question 33

Is compounded estradiol cream as safe as an FDA-approved product?

Accepted Answer

A compounded estradiol cream contains the same molecule as an approved product, but how much of it is absorbed has not been characterized the way an approved product's absorption has, and batch-to-batch consistency depends on the pharmacy. Compounded medications are not FDA-approved, are not reviewed by the FDA for safety or effectiveness, and are not equivalent to or interchangeable with any branded product. A 2020 National Academies review found little clinical basis for compounded hormones where an approved product will do — compounding exists for real reasons, such as an allergy to an ingredient or a form that is not commercially available, rather than as an upgrade.

Question 34

Are hormone pellets safe?

Accepted Answer

Hormone pellets deliver an amount that cannot be adjusted once it is under the skin and cannot easily be removed if it turns out to be more than you needed, which is the core of the objection to them rather than anything about the hormone itself. There is no FDA-approved pellet for menopausal hormone therapy in the United States, so pellets are compounded preparations, and major menopause societies advise against them on those grounds. ACT 2 Health does not offer pellets.

Question 35

Does calling a hormone bioidentical mean it has been tested for safety?

Accepted Answer

No. Bioidentical describes the structure of a molecule — identical to what the body makes — and says nothing about whether the product containing it was tested, manufactured consistently, or reviewed by anyone. Estradiol and micronized progesterone are both bioidentical and both exist as FDA-approved products, so the word does not distinguish a compounded preparation from an approved one, however often it is used to imply that it does. The safety questions that matter are which hormone, which route, which progestogen and your own history.

Question 36

Is an over-the-counter estrogen skin cream safe?

Accepted Answer

A cosmetic that avoids naming a hormone is avoiding it for regulatory reasons: anything containing estrogen is a drug in the United States, and anything that does not contain estrogen cannot do what estrogen does. Products in that space are either unapproved drugs or moisturizers with a suggestive label, and neither is a safe way to take a hormone — an over-the-counter cream containing real hormone is an unknown amount, absorbed to an unknown degree, with nobody responsible for the number on the jar. Estrogen for menopausal skin change is a prescription decision with monitoring, not a purchase.

Question 37

Is testosterone safe for women to take?

Accepted Answer

Testosterone in women is safe in the sense that matters only when the amount keeps levels inside the female physiological range, because exceeding it is where the harms come from — acne and unwanted hair growth first, and with sustained excess voice deepening and clitoral enlargement, which may not fully reverse. There is no FDA-approved testosterone product for women in the United States, so treatment means a compounded preparation or a male product used at a fraction of the male amount, which is why it has to be prescribed and monitored by someone who does it regularly and why self-directed use is genuinely risky. Monitoring exists to confirm the level has not run high, not to chase a number upward.

Question 38

Is testosterone therapy safe if I have sleep apnea?

Accepted Answer

Testosterone therapy can worsen obstructive sleep apnea, particularly where the apnea is untreated or severe, so the safer sequence is to screen for it and treat it first and then reassess whether testosterone treatment is still indicated. Treating the apnea often raises testosterone on its own, because fragmented sleep suppresses it — which makes the order of operations worth getting right. Snoring, witnessed pauses in breathing and daytime sleepiness belong in the conversation before a prescription rather than after one. See testosterone for the wider picture.

Question 39

Is oral testosterone harmful to the liver?

Accepted Answer

Modern oral testosterone undecanoate is absorbed through the lymphatic system rather than passing through the liver first, and it does not carry the liver toxicity of the older 17-alpha-alkylated oral androgens that gave oral testosterone its reputation. It has a different problem instead: increases in blood pressure have been reported with it, and it carries a boxed warning for that. Blood pressure monitoring is part of using it rather than an optional extra.

Question 40

Is oral testosterone or an injection safer?

Accepted Answer

Neither is generally safer — they fail in different directions. Oral testosterone carries a boxed warning for blood pressure; injections that produce pronounced peaks tend to push hematocrit and estradiol higher between administrations. Which risk matters more depends on your blood pressure, your hematocrit, your cardiovascular history and how reliably you can take something daily, which is what an assessment is for.

Question 41

Is it safe to take peptides alongside hormone therapy?

Accepted Answer

Peptides cannot be assessed as a category: some are approved medicines with known safety profiles, and many marketed compounds have no human safety data and are supplied outside pharmaceutical manufacturing standards. Where a peptide is considered alongside hormone therapy at ACT 2 Health, it is for eligible patients under clinical evaluation and ongoing monitoring, with the whole hormonal picture in view. The version that goes wrong is compounds bought online and stacked on top of a prescription, because nobody is looking at the combination. See peptides for the category.

Hormone Therapy Safety and Risk

We measure first. Then we act.